Clinical | Published:

Clinical uses of botulinum toxin A in smile aesthetic modification

BDJ volume 225, pages 502506 (28 September 2018) | Download Citation

Abstract

In this article we review the pharmacodynamics of commercially available preparations of botulinum toxin type A, and discuss the potential uses of the drug in smile modification. A major emphasis is placed on applications relevant to modern dental practice, and to the complications arising from its use. Botulinum toxin A, when applied correctly, is a safe and effective means of achieving aesthetic smile modification, with limited data on any demonstrable long-term adverse effects.

Key points

  • Provides information regarding a drug that is increasingly used by dental practitioners worldwide.

  • Provides education on alternative options for correction or camouflage of dentofacial aesthetics of the lower face.

  • Summarises the available case reports and research articles on use of botulinum toxin for lower facial and smile aesthetics, a major component of modern dental practice.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    , , et al. A multicentre, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J Am Acad Dermatol 2002; 46: 840–849.

  2. 2.

    , . Facial aesthetics: is botulinum toxin treatment effective and safe? A systematic review of randomised controlled trials. Br Dent J 2009; 207: E9; discussion 216–217.

  3. 3.

    . Safeguards introuced for provision of injectable cosmetic treatments. Br Dent J 2010; 208: 279.

  4. 4.

    , , et al. Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. Nature 1993; 365: 160–163.

  5. 5.

    , , . Botulinum toxin: mechanism of presynaptic blockade. Science 1976; 193: 1256–1258.

  6. 6.

    , , . Botulinum toxin: mechanisms of action. Arq Neuropsiquiatr 2005; 63: 180–185.

  7. 7.

    . Complications and Adverse Reactions With the Use of Botulinum Toxin. Dis Mon 2002; 48: 336–356.

  8. 8.

    , . Botox and Dysport: is there a dose conversion ratio in dermatology and aesthetic medicine? J Am Acad Dermatol 2010; 62: 346–347.

  9. 9.

    , . Diffusion characteristics of botulinum neurotoxin products and their clinical significance in cosmetic applications. J Cosmet Laser Ther 2007; 9 (Suppl 1): 17–22.

  10. 10.

    , , , , . Pilot study comparing the diffusion of two formulations of botulinum toxin type A in patients with forehead hyperhidrosis. Dermatol Surg 2007; 33: S37–S43.

  11. 11.

    Allergan. Botox Cosmetic-botulinim toxin type A injection powder, lypophilized for solution. 2015.

  12. 12.

    . Predicting soft tissue profile changes concurrent with orthodontic treatment. Angle Orthod 1990; 60: 199–206.

  13. 13.

    , . Special feature: Botox treatment for expressive facial lines and wrinkles. Curr Opin Otolaryngol Head Neck Surg 2000; 8: 357–361.

  14. 14.

    , . Mentalis and orbicularis activity in children with incompetent lips: an electromyographic and cephalometric study. Act Odontologica 1975; 33: 355–363.

  15. 15.

    . Measuring the physical in physical attractiveness: quasi-experiments on the sociobiology of female facial beauty. J Pers Soc Psychol 1986; 50: 925.

  16. 16.

    . MOC-PS(SM) CME article: genioplasty. Plst Reconstr Surg 2008; 121: 1–7.

  17. 17.

    , , . Chin, nose, and lips. Normal ratios in young men and women. Am J Orthod Dentofacial Orthop 1994; 106: 518–523.

  18. 18.

    , , . What do women want? Facialmetric assessment of multiple motives in the perception of male physical attractiveness. J Pers Soc Psychol 1990; 59: 61–72.

  19. 19.

    . Aesthetic refinements in genioplasty: the role of the labiomental fold. Plast Reconstr Surg 1991; 88: 760–767.

  20. 20.

    , . Chin surgery III: revelations. Plast Reconstr Surg 2003; 111: 1542–1550.

  21. 21.

    , , . A double-blinded, placebo-controlled study of Botox for the treatment of subjects with chin rhytids. J Drugs Dermatol 2005; 4: 417–422.

  22. 22.

    , . Aesthetic botulinum A toxin in the mid and lower face and neck. Dermatol Surg 2003; 29: 468–476.

  23. 23.

    , . Cosmetic uses of botulinum toxins for lower aspects of the face and neck. Clin Dermatol 2004; 22: 18–22.

  24. 24.

    , . The dynesthetic interpretation of the dentogenic concept. J Prosth Dent 1958; 8: 558–581.

  25. 25.

    . The importance of incisor positioning in the esthetic smile: the smile arc. Am J Orthod Dentofacial Orthop 2001; 120: 98–111.

  26. 26.

    , . The aesthetic smile: diagnosis and treatment. Periodontol 2000 1996; 11: 18–28.

  27. 27.

    , , . Some esthetic factors in a smile. J Prosthet Dent 1984; 51: 24–28.

  28. 28.

    . Differential diagnosis and treatment of excess gingival display. Pract Periodontics Aesthet Dent 1999; 11: 265–272.

  29. 29.

    , Cosmetic denervation of the muscles of facial expression with botulinum toxin. A dose-response study. Dermatol Surg 1996; 22: 39–43.

  30. 30.

    . The effect of botulinum toxin injections on the nasolabial fold. Plast Reconstr Surg 2003; 112(5 Suppl): 66S–72S; discussion 3S–4S.

  31. 31.

    , . Gummy smile and botulinum toxin: a new approach based on the gingival exposure area. J Am Acad Dermatol 2010; 63: 1042–1051.

  32. 32.

    , , , . Botox as an adjunct to orthognathic surgery for a case of severe vertical maxillary excess. J Maxillofac Oral Surg 2011; 10: 266–270.

  33. 33.

    . Botulinum toxin type A (Botox) for the neuromuscular correction of excessive gingival display on smiling (gummy smile). Am J Orthod Dentofacial Orthop 2008; 133: 195–203.

  34. 34.

    , . The dynamics of the maxillary incisor and the upper lip: a cross-sectional study of resting and smile hard tissue characteristics. World J Orthod 2002; 3: 313–320.

  35. 35.

    , . Injectable neurotoxins and fillers: There is no free lunch. Clin Dermatol 2011; 29: 678–690.

  36. 36.

    , . , , Reloxin Investigational Group. An Analysis of the Long-Term Safety Data of Repeat Administrations of Botulinum Neurotoxin Type A-ABO for th Treatment of Glabellar Lines. Aesthet Surg J 2009; 29: 43–49.

Download references

Author information

Affiliations

  1. Lead Registrar, Oral and Maxillofacial Surgery The Royal Dental Hospital of Melbourne 720 Swanston St, Carlton Australia, 3,053 E

    • S. N. Delpachitra
  2. Oral and Maxillofacial Surgery Resident The Royal Dental Hospital of Melbourne 720 Swanston St, Carlton Australia, 3,053 E

    • A. W. Sklavos
  3. Consultant Oral and Maxillofacial Surgeon, The Royal Melbourne Hospital 300 Grattan Street, Parkville Australia 3050

    • M. Dastaran

Authors

  1. Search for S. N. Delpachitra in:

  2. Search for A. W. Sklavos in:

  3. Search for M. Dastaran in:

Corresponding author

Correspondence to S. N. Delpachitra.

About this article

Publication history

Accepted

Published

DOI

https://doi.org/10.1038/sj.bdj.2018.755